These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

366 related articles for article (PubMed ID: 34143881)

  • 1. Antimicrobial Resistance Trends in Urine Escherichia coli Isolates From Adult and Adolescent Females in the United States From 2011 to 2019: Rising ESBL Strains and Impact on Patient Management.
    Kaye KS; Gupta V; Mulgirigama A; Joshi AV; Scangarella-Oman NE; Yu K; Ye G; Mitrani-Gold FS
    Clin Infect Dis; 2021 Dec; 73(11):1992-1999. PubMed ID: 34143881
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Older patient age and prior antimicrobial use strongly predict antimicrobial resistance in Escherichia coli isolates recovered from urinary tract infections among female outpatients.
    Mitrani-Gold FS; Kaye KS; Gupta V; Mulgirigama A; Trautner BW; Scangarella-Oman NE; Yu KC; Ye G; Joshi AV
    PLoS One; 2023; 18(5):e0285427. PubMed ID: 37167277
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevalence, regional distribution, and trends of antimicrobial resistance among female outpatients with urine Klebsiella spp. isolates: a multicenter evaluation in the United States between 2011 and 2019.
    Kaye KS; Gupta V; Mulgirigama A; Joshi AV; Ye G; Scangarella-Oman NE; Yu K; Mitrani-Gold FS
    Antimicrob Resist Infect Control; 2024 Feb; 13(1):21. PubMed ID: 38355621
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A multicenter analysis of trends in resistance in urinary Enterobacterales isolates from ambulatory patients in the United States: 2011-2020.
    Dunne MW; Aronin SI; Yu KC; Watts JA; Gupta V
    BMC Infect Dis; 2022 Feb; 22(1):194. PubMed ID: 35227203
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Trends in the Prevalence of Antimicrobial Resistance in Escherichia coli Isolated from Outpatient Urine Cultures in French Amazonia.
    Nkontcho Djamkeba F; Sainte-Rose V; Lontsi Ngoulla GR; Roujansky A; Abboud P; Walter G; Houcke S; Demar M; Kallel H; Pujo JM; Djossou F
    Am J Trop Med Hyg; 2024 Aug; 111(2):287-296. PubMed ID: 38917783
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The burden of antimicrobial resistance among urinary tract isolates of Escherichia coli in the United States in 2017.
    Critchley IA; Cotroneo N; Pucci MJ; Mendes R
    PLoS One; 2019; 14(12):e0220265. PubMed ID: 31821338
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Prevalence and antimicrobial susceptibility of extended-spectrum beta-lactamase producing urinary isolates of Escherichia coli in outpatients].
    Marković T; Jeinić L; Smitran A; Petković M
    Srp Arh Celok Lek; 2013; 141(11-12):775-9. PubMed ID: 24502096
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased rates of extended-spectrum beta-lactamase isolates in patients hospitalized with culture-positive urinary Enterobacterales in the United States: 2011 - 2020.
    Aronin SI; Dunne MW; Yu KC; Watts JA; Gupta V
    Diagn Microbiol Infect Dis; 2022 Aug; 103(4):115717. PubMed ID: 35635889
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasmid-mediated AmpC beta-lactamase-producing Escherichia coli causing urinary tract infection in the Auckland community likely to be resistant to commonly prescribed antimicrobials.
    Drinkovic D; Morris AJ; Dyet K; Bakker S; Heffernan H
    N Z Med J; 2015 Mar; 128(1410):50-9. PubMed ID: 25829039
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Extended-spectrum β-lactamase-producing Gram-negative pathogens in community-acquired urinary tract infections: an increasing challenge for antimicrobial therapy.
    Meier S; Weber R; Zbinden R; Ruef C; Hasse B
    Infection; 2011 Aug; 39(4):333-40. PubMed ID: 21706226
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of Predictive Models to Inform a Novel Risk Categorization Framework for Antibiotic Resistance in Escherichia coli-Caused Uncomplicated Urinary Tract Infection.
    Shields RK; Cheng WY; Kponee-Shovein K; Indacochea D; Gao C; Kuwer F; Joshi AV; Mitrani-Gold FS; Schwab P; Ferrinho D; Mahendran M; Pinheiro L; Royer J; Preib MT; Han J; Colgan R
    Clin Infect Dis; 2024 Aug; 79(2):295-304. PubMed ID: 38573310
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increasing prevalence of ciprofloxacin resistance in extended-spectrum-β-lactamase-producing Escherichia coli urinary isolates.
    Bonkat G; Müller G; Braissant O; Frei R; Tschudin-Suter S; Rieken M; Wyler S; Gasser TC; Bachmann A; Widmer AF
    World J Urol; 2013 Dec; 31(6):1427-32. PubMed ID: 23358791
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Occurrence and Genomic Characterization of Clone ST1193 Clonotype 14-64 in Uncomplicated Urinary Tract Infections Caused by Escherichia coli in Spain.
    García-Meniño I; Lumbreras P; Lestón L; Álvarez-Álvarez M; García V; Hammerl JA; Fernández J; Mora A
    Microbiol Spectr; 2022 Jun; 10(3):e0004122. PubMed ID: 35604206
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of the COVID-19 pandemic on extended-spectrum β-lactamase producing Escherichia coli in urinary tract and blood stream infections: results from a nationwide surveillance network, Finland, 2018 to 2022.
    Ilmavirta H; Ollgren J; Räisänen K; Kinnunen T; Hakanen AJ; Rantakokko-Jalava K; Jalava J; Lyytikäinen O
    Antimicrob Resist Infect Control; 2024 Jul; 13(1):72. PubMed ID: 38971782
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antimicrobial susceptibilities of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in health care-associated urinary tract infection: focus on susceptibility to fosfomycin.
    Cho YH; Jung SI; Chung HS; Yu HS; Hwang EC; Kim SO; Kang TW; Kwon DD; Park K
    Int Urol Nephrol; 2015 Jul; 47(7):1059-66. PubMed ID: 26026972
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential Trends in Extended-Spectrum Beta-Lactamase-Producing
    Raphael E; Chambers HF
    Microb Drug Resist; 2021 Feb; 27(2):154-161. PubMed ID: 32589493
    [No Abstract]   [Full Text] [Related]  

  • 17. Trends in antimicrobial resistance among urinary tract infection isolates of Escherichia coli from female outpatients in the United States.
    Karlowsky JA; Kelly LJ; Thornsberry C; Jones ME; Sahm DF
    Antimicrob Agents Chemother; 2002 Aug; 46(8):2540-5. PubMed ID: 12121930
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antimicrobial Resistance and Molecular Characterization of Extended-Spectrum β-Lactamases of Escherichia coli and Klebsiella spp. Isolates from Urinary Tract Infections in Southern Brazil.
    Pereira JL; Volcão LM; Klafke GB; Vieira RS; Gonçalves CV; Ramis IB; da Silva PEA; von Groll A
    Microb Drug Resist; 2019 Mar; 25(2):173-181. PubMed ID: 30133334
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multidrug resistance and risk factors associated with community-acquired urinary tract infections caused by Escherichia coli in Venezuela.
    Guzmán M; Salazar E; Cordero V; Castro A; Villanueva A; Rodulfo H; De Donato M
    Biomedica; 2019 May; 39(s1):96-107. PubMed ID: 31529852
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antimicrobial Activity of Gepotidacin Tested against Escherichia coli and Staphylococcus saprophyticus Isolates Causing Urinary Tract Infections in Medical Centers Worldwide (2019 to 2020).
    Arends SJR; Butler D; Scangarella-Oman N; Castanheira M; Mendes RE
    Antimicrob Agents Chemother; 2023 Apr; 67(4):e0152522. PubMed ID: 36877017
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.